ITEM 1. FINANCIAL STATEMENTS
The unaudited financial statements for the quarter ended May 31, 2022 immediately follow.
TRIDENT BRANDS INCORPORATED
Consolidated Balance Sheets
(Unaudited)
| As of | As of |
| May 31, | November 30, |
| 2022 | 2021 |
| (unaudited) |
| ASSETS |
| Current Assets |
| Cash | $ | 12,389 | $ | 7,653 |
| Accounts Receivable, net of allowance for doubtful accounts of $ 11,286 and $ 160,210 , respectively | 1,073 | 12,358 |
| Inventory, net of reserves of $ 401,606 and $ 401,606 , respectively | 735,476 | 881,924 |
| Prepaid and other current assets | 419 | 158,146 |
| Total Current Assets | 749,357 | 1,060,081 |
| TOTAL ASSETS | $ | 749,357 | $ | 1,060,081 |
| LIABILITIES & STOCKHOLDERS' DEFICIT |
| Current Liabilities |
| Accounts Payable | $ | 549,941 | $ | 524,207 |
| Accrued Liabilities | 10,485,801 | 9,405,833 |
| Total Current Liabilities | 11,035,742 | 9,930,040 |
| Convertible Debt, net of discount of $ 0 and $ 0 , respectively | 22,300,000 | 22,300,000 |
| Total Liabilities | 33,335,742 | 32,230,040 |
| Stockholders' Deficit |
| Common stock, $ 0.001 par value, 300,000,000 shares authorized; 37,311,887 and 33,311,887 shares issued and outstanding as of May 31, 2022 and November 30, 2021 respectively | 37,312 | 32,312 |
| Additional paid-in capital | 11,608,630 | 11,492,630 |
| Non-Controlling Interest in Subsidiary | ( 633,495 | ) | ( 490,852 | ) |
| Accumulated Deficit | ( 43,598,832 | ) | ( 42,205,049 | ) |
| Total Stockholders' Deficit | ( 32,586,385 | ) | ( 31,169,959 | ) |
| TOTAL LIABILITIES & STOCKHOLDERS' DEFICIT | $ | 749,357 | $ | 1,060,081 |

See Notes to Unaudited Consolidated Financial Statements
| 6 |

| TRIDENT BRANDS INCORPORATED |
| Consolidated Statements of Operations (Unaudited) |
| Three Months | Three Months | Six Months | Six Months |
| Ended | Ended | Ended | Ended |
| May 31, | May 31, | May 31, | May 31, |
| 2022 | 2021 | 2022 | 2021 |
| Revenues, net | $ | 125,280 | $ | 46,243 | $ | 125,280 | $ | 190,291 |
| Cost of Sales | 146,448 | 24,580 | 146,448 | 103,368 |
| Gross Profit | ( 21,168 | ) | 21,663 | ( 21,168 | ) | 86,923 |
| General & Administrative Expenses | ( 528,103 | ) | ( 537,978 | ) | ( 945,412 | ) | ( 942,262 | ) |
| Loss from Operations | ( 549,271 | ) | ( 516,315 | ) | ( 966,580 | ) | ( 855,339 | ) |
| Other Income (Expenses) |
| Interest Expense, net | ( 234,171 | ) | ( 200,008 | ) | ( 569,846 | ) | ( 400,341 | ) |
| Total Other Income (Expenses) | ( 234,171 | ) | ( 200,008 | ) | ( 569,846 | ) | ( 400,341 | ) |
| Net Loss | $ | ( 783,442 | ) | $ | ( 716,323 | ) | $ | ( 1,536,426 | ) | $ | ( 1,255,680 | ) |
| Net loss attributable to Trident | ( 703,825 | ) | ( 646,092 | ) | ( 1,393,783 | ) | ( 1,181,590 | ) |
| Net loss attributable to Non-Controlling Interests | ( 79,617 | ) | ( 70,231 | ) | ( 142,643 | ) | ( 74,090 | ) |
| Loss per share - Basic and diluted | $ | ( 0.02 | ) | $ | ( 0.02 | ) | $ | ( 0.04 | ) | $ | ( 0.04 | ) |
| Weighted average number of common shares outstanding - Basic and diluted | 37,181,452 | 32,311,887 | 35,267,931 | 32,311,887 |

See Notes to Unaudited Consolidated Financial Statements
| 7 |

TRIDENT BRANDS INCORPORATED
Consolidated Statements of Changes in Stockholders’ Deficit
For the six months ended May 31, 2022 and May 31, 2021
(Unaudited)
| Common | Additional | Non- |
| Common | Stock | Paid-in | Accumulated | Controlling |
| Stock | Amount | Capital | Deficit | Interest | Total |
| Balance, November 30, 2020 | 32,311,887 | $ | 32,312 | $ | 11,458,630 | $ | ( 39,522,278 | ) | $ | ( 387,147 | ) | $ | ( 28,418,483 | ) |
| Net loss, February 28, 2021 | - | - | - | ( 535,498 | ) | ( 3,859 | ) | ( 539,357 | ) |
| Balance, February 28, 2021 | 32,311,887 | $ | 32,312 | $ | 11,458,630 | $ | ( 40,057,776 | ) | $ | ( 391,006 | ) | $ | ( 28,957,840 | ) |
| NCI Investment in Brain Armor | 300,000 | 300,000 |
| Net loss, May 31, 2021 | - | - | - | ( 646,091 | ) | ( 70,231 | ) | ( 716,323 | ) |
| Balance, May 31, 2021 | 32,311,887 | $ | 32,312 | $ | 11,458,630 | $ | ( 40,703,867 | ) | $ | ( 161,237 | ) | $ | ( 29,374,162 | ) |
| Balance, November 30, 2021 | 33,311,887 | $ | 33,312 | $ | 11,492,630 | $ | ( 42,205,049 | ) | $ | ( 490,852 | ) | $ | ( 31,169,959 | ) |
| Net loss, February 28, 2022 | - | - | - | ( 689,958 | ) | ( 63,026 | ) | ( 752,984 | ) |
| Balance, February 28, 2022 | 33,311,887 | $ | 33,312 | $ | 11,492,630 | $ | ( 42,895,007 | ) | $ | ( 553,878 | ) | $ | ( 31,922,943 | ) |
| Issuance of Common Shares for services | 4,000,000 | $ | 4,000 | $ | 116,000 | $ | 120,000 |
| Net loss, May 31, 2022 | - | - | - | ( 703,825 | ) | ( 79,617 | ) | ( 783,441 | ) |
| Balance, May 31, 2022 | 37,311,887 | $ | 37,312 | $ | 11,608,630 | $ | ( 43,598,832 | ) | $ | ( 633,495 | ) | $ | ( 32,586,385 | ) |

See Notes to Unaudited Consolidated Financial Statements
| 8 |

TRIDENT BRANDS INCORPORATED
Consolidated Statements of Cash Flows
(Unaudited)
| Six Months | Six Months |
| Ended | Ended |
| May 31, | May 31, |
| 2022 | 2021 |
| CASH FLOWS FROM OPERATING ACTIVITIES |
| Net loss | $ | ( 1,536,426 | ) | $ | ( 1,255,680 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |
| Issuance of Common Shares for services | 120,000 | - |
| Provision for bad debts | - | 2,340 |
| Changes in operating assets and liabilities: |
| Accounts receivable | 11,285 | ( 10,061 | ) |
| Prepaid expenses | 157,727 | 86,272 |
| Inventory | 146,448 | 111,980 |
| Accounts payable and accrued liabilities | 1,105,702 | 808,503 |
| Cash provided by (used in) operating activities | 4,736 | ( 256,646 | ) |
| CASH FLOWS FROM FINANCING ACTIVITIES |
| Proceeds from NCI Investment in Brain Armor | - | 300,000 |
| Cash provided by financing activities | - | 300,000 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 4,736 | 43,354 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 7,653 | 88,007 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | 12,389 | $ | 131,361 |
| Supplemental disclosure of cash flow information: |
| Cash paid for: |
| Income taxes | - | - |
| Interest | - | - |

See Notes to Unaudited Consolidated Financial Statements
| 9 |

TRIDENT BRANDS INCORPORATED
Notes to Consolidated Financial Statements
May 31, 2022
(Unaudited)
NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS
Trident Brands Incorporated “we”, “our”, “the Company”) was incorporated under the laws of the State of Nevada on November 5, 2007.
The Company is focused on the development of high growth branded and private label consumer products and ingredients within the nutritional supplement, life sciences and food and beverage categories. The Company is in its early growth stage and has transitioned out of its shell status with the Super 8-K filing at the end of August, 2014. Activities to date have focused on capital formation, organizational development and execution of its branded and private label consumer products and ingredients business plan.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Form 10-K filed with SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for fiscal 2021 as reported in the Form 10-K have been omitted.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates. The ultimate impact from COVID-19 on the Company’s operations and financial results during 2022 will depend on, among other things, the ultimate severity and scope of the pandemic, the pace at which governmental and private travel restrictions and public concerns about public gatherings will ease, the rate at which historically large increases in unemployment rates will decrease, if at all, and whether, and the speed with which the economy recovers. We are not able to fully quantify the impact that these factors will have on our financial results during the remainder of 2022 and beyond, but expect developments related to COVID-19 to continue to materially affect the Company’s financial performance during 2022.
Customer Concentration
One customer accounted for 100 .0% of total revenue for the six month period ended May 31, 2022 compared to two customers who accounted for 19.9 % and 11.5 % of total revenue for the six month period ended May 31, 2021. Two customers accounted for 66.5 % and 33.5 % of total accounts receivable as of May 31, 2022 compared to two customers for 39.4 % and 29.2 % as of May 31, 2021.
| 10 |

Fair Value of Financial Instruments
The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair Value Measurements and Disclosures”. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.
Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures.
Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.
Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.
The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable and note payable. The fair value of the Company’s long-term debt is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value. As of May 31, 2022 the Company did not have any financial assets or liabilities measured and recorded at fair value on the Company’s consolidated balance sheets on a recurring basis.
Recent Accounting Pronouncements
The Company has evaluated recent accounting pronouncements through the date the financial statements were issued and filed with the Securities and Exchange Commission and believe that there are none that will have a material impact on the Company’s financial statements.
NOTE 3. GOING CONCERN
The accompanying interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.
As of May 31, 2022, the Company had $ 12,389 in cash and a working capital deficit of $ 10,286,385 . The Company also has generated losses and has an accumulated deficit as of May 31, 2022. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless Management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
| 11 |

NOTE 4. WARRANTS AND OPTIONS
The following table represents stock option activity for the six month period ended May 31, 2022:
| Number of Options | Weighted Average Exercise Price | Contractual Life in Years | Intrinsic Value |
| Outstanding - November 30, 2021 | 1,532,500 | $ | 0.40 | 1.02 |
| Exercisable - November 30, 2021 | 1,532,500 | $ | 0.40 | 1.02 | $ | - 0 - |
| Granted | - 0 - |
| Exercised or Vested | - 0 - |
| Forfeited or Expired | 300,000 |
| Outstanding - May 31, 2022 | 1,232,500 | $ | 0.40 | .52 |
| Exercisable - May 31, 2022 | 1,232,500 | $ | 0.40 | .52 | $ | - 0 - |

As of May 31, 2022, the Company has no outstanding warrants. All the outstanding warrants have expired.
NOTE 5. RELATED PARTY TRANSACTIONS
On October 15, 2021, a Promissory Note was issued to Anthony Pallante, Chairman and a significant stockholder of the Company. The Note is unsecured and was issued in consideration for payments made by Mr. Pallante on behalf of the Company to creditors in satisfaction of Company obligations. Mr. Pallante loaned the Company $ 20,101 . The Note bears Interest at a rate of 8 % per annum. All unpaid principal and accrued interest shall be due and payable upon demand by the Holder at any time subsequent to six (6) months from the date the notes were issued. As of May 31, 2022, Mr. Pallante made additional payments of $ 37,036 for a total of $ 57,137 .
NOTE 6. CONVERTIBLE DEBT
On January 29, 2015, the Company entered into a securities purchase agreement with a non-US institutional investor whereby it agreed to sell an aggregate principal amount of $ 2,300,000 of senior secured convertible debentures, convertible into shares of the Company’s common stock.
The Company received $ 1,800,000 of the funds from the transaction on February 5, 2015. The balance of $ 500,000 was received on May 14, 2015. These convertible notes were subsequently acquired by Fengate Trident, LP (‘Fengate”) on April 28, 2017.
The convertible debentures are convertible into shares of the Company’s common stock at an initial conversion price of $ 0.71 per share, for an aggregate of up to 3,239,437 shares. The debentures originally accrued interest at 6 % per annum. On September 26, 2016 the Company entered into an amendment agreement related to these convertible debentures whereby the applicable interest rate was increased from 6 % to 8% and provisions added to allow the investor to transfer, sell or hypothecate the convertible notes subject to applicable securities laws. The maturity date of the notes was also extended through September 30, 2019 . We considered ASC Topic 470-50, Debt Modifications and Extinguishments, and determined that the modification was not deemed substantial.
Due to the note being convertible to common shares of the Company, a beneficial conversion feature analysis was performed. The intrinsic value of the conversion feature was $ 647,888 which was recognized as debt discount. As of November 30, 2017, the full amount of the debt discount has been amortized.
On September 26, 2016, the Company entered into a securities purchase agreement with a non-US institutional investor, pursuant to which, in consideration for proceeds of $ 4,100,000 , the Company issued a secured convertible promissory note in the amount of $ 4,100,000 . Pursuant to the securities purchase agreement, the investor has agreed, from time to time after January 1, 2017, to make additional investments at the Company’s request of up to $ 5,900,000 . On May 9, 2017, the Company received the second tranche of funding with proceeds of $4,400,000 and on May 16, 2018 the third tranche of $1,500,000 for a total investment by the investor of $ 10,000,000 .
The Company used the proceeds of the secured convertible note for general working capital purposes including settlement of accounts payable and repayment of mature loans.
| 12 |

In consideration of each advance made by the investor pursuant to the securities purchase agreement, the Company issued to the investor a convertible promissory note of equal value, maturing on September 30, 2019, and bearing interest at the rate of 8% per annum. Each note was secured in first priority against the present and after acquired assets of the Company and was convertible in whole or in part at the option of the holder into common shares of the Company at a conversion price of $ 0.60 per share, for an aggregate of up to 16,666,667 shares. These convertible notes were subsequently acquired by Fengate on April 28, 2017.
Due to the notes being convertible to common shares of the Company, a beneficial conversion feature analysis was performed. The intrinsic value of the conversion feature of the notes amounted to $ 3,333,334 and was recognized as a debt discount. As of November 30, 2021, $ 3,333,334 of the debt discount was amortized to interest of which $ 334,988 was amortized during the current year compared to $ 855,987 in the prior year. As of November 30, 2021, the debt discount was fully amortized.
On November 30, 2018 the Company and Fengate entered into a Securities Purchase Amendment Agreement ("SPS") pursuant to which the Company has agreed to issue to Fengate additional convertible promissory notes (collectively, the “2018 and 2019 Convertible Notes”) of up to $ 10,000,000 , subject to certain terms and conditions. Each portion of the principal amount advanced pursuant to the SPA boar interest at the rate of twelve percent ( 12 %) per annum and will be payable monthly in arrears to Fengate. Outstanding principal and interest will continue to be secured by the general security agreement dated September 26, 2016, which forms a part of the Agreement. The holder of the note may also elect from time to time to convert all or a portion of the outstanding principal and interest into common shares of the Company at a 25% discount to the average closing price of the common shares during the 10 trading days immediately prior to the applicable conversion date. The 2018 and 2019 Convertible Notes (aka “Amended SPA Notes”) were extended until December 1, 2021. The Maturity Date of the Amended SPA Notes was extended to November 30, 2025, as described below.
On November 30, 2018 the Company received the first tranche of funding with proceeds of $ 3,400,780 . The 2nd tranche of $ 2,804,187 was received on April 13, 2019. The 3rd tranche of $ 3,795,033 less $ 936,168 withheld for interest payments up to and including June 30, 2020 was received on November 6, 2019. On March 5, 2020, the 2018 and 2019 Convertible Notes were amended to increase the amount of the 3rd tranche by $ 936,168 representing the amount previously withheld as interest payment. The withheld interest was subsequently received on March 12, 2020.
The Company analyzed the embedded conversion option on the convertible notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option on the 2018 Convertible Note qualified for derivative accounting. The Company used the Black-Scholes model to value the embedded conversion option at $ 892,000 on the issuance date of November 30, 2018, $ 1,911,256 on the issuance date of April 13, 2019 and $ 1,696,933 on the issuance date of November 6, 2019. The assumptions used were a discount rate of 2.80 %, 1.96 % and 1.96 %; volatility rate of 79.57 %, 104.70 % and 107.3 %; and a term of 1.50 , 1.13 and 0.57 years respectively. The fair values of the embedded conversion options were recorded as debt discount and were amortized over the term of the 2018 and 2019 Convertible Notes. Amortization of debt discount for the years ended November 30, 2021 and 2020 was $ 1,885,587 and $ 1,857,295 , respectively. The unamortized discount as of November 30, 2021 is $ 0 .
On January 9, 2020 the Company and Fengate entered into an Amendment to Convertible Promissory Notes Agreement to amend the terms of the convertible notes issued on February 5, 2015 (US$ 1,800,000 ), May 14, 2015 (US$ 500,000 ), September 26, 2016 (US$ 4,100,000 ), May 9, 2017 (US$ 4,400,000 ) and May 16, 2018 (US$ 1,500,000 ) (collectively the “2016 Convertible Notes”). Pursuant to the Amendment, Fengate has agreed to convert all of the 2016 Notes on or before the earlier to occur of (i) the maturity date of the 2016 Convertible Notes and (ii) the Company raising new equity investment of not less than US$2,000,000, on terms mutually acceptable to Fengate and the Company (subject to Fengate’s regulatory considerations). Conversion of the 2016 Notes will occur in a single conversion transaction at a price that is equal to a 25% discount to the average closing price of the Company’s common stock for the 10 trading days immediately prior to the conversion date, with the exact structure of the conversion to be determined by the parties. On June 3, 2020 the maturity date was extended from May 31 to December 31, 2020 . The Amendment also extended the maturity date of the 2018 and 2019 Convertible Notes to December 1, 2021 .
The Company analyzed the embedded conversion option on the amended “2016 Convertible Notes” for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option qualified for derivative accounting. On January 9, 2020 the Company used the Black-Scholes model to value the embedded conversion options at $ 7,965,083 . The assumptions used were a discount rate of 1.96 %, volatility rate of 148.8 %; and a term of 0.39 years respectively. The modification resulted in $ 3,981,221 of APIC previously recorded for beneficial conversion feature of these convertible notes being reclassified as derivative liability.
On November 30, 2020, the Company entered into a fourth amendment of the 2016 Convertible Notes and the 2018 and 2019 Convertible Notes wherein the Company will issue to Fengate 29,432,320 shares of Company Preferred Stock (representing $ 17,659,392 of principal and interest converted into Preferred Stock at the rate of $ 0.60 per share), in full and complete satisfaction of (i) all amounts owing under the 2016 Convertible Notes through November 30, 2021 (including accrued interest thereon) and (ii) all accrued interest on the 2018 and 2019 Convertible Notes through November 30, 2021. The conversion was originally expected to occur by the end of June, 2021. The 2018 and 2019 Convertible Notes were further amended to (i) eliminate the conversion feature of such notes, (ii) provide for a simple interest rate of 8 % per annum, with the first 2 years of interest payable at maturity of the 2018 and 2019 Convertible Notes and the last three years of interest payable quarterly beginning February 28, 2023; and (iii) extend the maturity of such notes until November 30, 2025. Pursuant to this amendment, all notes no longer qualified for derivative accounting. As such, the value of the embedded conversion options of all notes of $ 5,494,363 was credited to additional paid in capital.
The consummation of the foregoing transaction is subject to (i) authorization and issuance of the Preferred Stock, which is subject to approval of the requisite number of common shares of the Company, in accordance with Nevada law and the Company’s organizational documents, and (ii) Note Holder’s obligation to remain in compliance with regulations governing its ownership of voting shares.
| 13 |

The Company and Note Holder had previously undertaken to consummate the foregoing transactions no later than June 30, 2021. On March 29, 2022, the Board of Directors approved an amendment to our Certificate of Incorporation which authorizes 29,432,320 shares of Company Preferred Stock. On March 30, 2022, more than a majority in interest of our common shares by written consent approved such amendment to our Certificate of Incorporation. The effectiveness of this shareholder approval is pending the filing of an information statement with the SEC and mailing to our shareholders. The Company expects to consummate this transaction prior to September 30, 2022
We considered ASC Topic 470-50, Debt Modifications and Extinguishments in connection with the amendment of the interest rate and maturity date of the 2018 and 2019 Convertible Notes and determined that the modification would be considered a debt extinguishment. The unamortized discount of $ 1,092,295 at the date of amendment was recognized as a loss on debt extinguishment for the year ended November 30, 2020
NOTE 7. NON-CONTROLLING INTEREST INVESTMENT IN BRAIN ARMOR, INC.
On March 30, 2021, a non-US investor subscribed to the acquisition of 333,333 units of the Company’s Brain Armor Inc subsidiary. Each unit is comprised of one share of Brain Armor stock, $ 0.001 par value and a common stock purchase warrant evidencing the right to purchase one share of Common Stock. The 333,333 units were sold at a per unit price of USD $ 0.30 for an aggregate purchase price of USD $ 100,000 which was received by the Company on March 30, 2021. The vesting and exercise prices of the warrants are as follows:
| ● | 1/3 of shares shall be exercisable 6 months after the subscription date at an exercise price of $ 0.45 per share |
| ● | 1/3 of shares shall be exercisable 12 months after the subscription date at an exercise price of $ 0.60 per share |
| ● | 1/3 of shares shall be exercisable 18 months after the subscription date at an exercise price of $ 0.75 per share |

On May 5, 2021, a US investor subscribed to the acquisition of 3,333,333 units of the Company’s Brain Armor Inc subsidiary, with each unit being comprised of one share of Brain Armor stock, $ 0.001 par value and a common stock purchase warrant evidencing the right to purchase one share of Common Stock at a per unit price of USD $ 0.30 for an aggregate purchase price of USD $ 1,000,000 of which $ 100,000 was received by the Company on May 13, 2021 and $ 100,000 on May 27, 2021. This subscription agreement has since been terminated by mutual agreement of Brain Armor Inc. and the investor.
The vesting and exercise prices of the warrants are as follows:
| ● | 1/3 of shares shall be exercisable 6 months after the subscription date at an exercise price of $ 0.45 per share |
| ● | 1/3 of shares shall be exercisable 12 months after the subscription date at an exercise price of $ 0.60 per share |
| ● | 1/3 of shares shall be exercisable 18 months after the subscription date at an exercise price of $ 0.75 per share |

| 14 |

NOTE 8. COMMITMENTS AND CONTINGENCIES
Everlast License Agreement
On December 23, 2013, the Company entered into a Deed of Assignment Agreement with Everlast World’s Boxing Headquarters Corporation, International Brand Management Limited, Sports Nutrition Products Incorporated and Manchester Capital Incorporated wherein Everlast, International Brand, Sports Nutrition and Manchester Capital are parties to a trade mark license and Sports Nutrition, a New York corporation, has assigned its interest in the trade mark license to the Company. Pursuant to the terms of the assignment agreement, Sports Nutrition Products Incorporated, a wholly owned subsidiary of Trident Brands Incorporated, assigned all of its rights, title, interest and benefit to the trade mark license to the Company effective December 23, 2013 and the Company assumed all of the obligations of Sports Nutrition Products Incorporated under the license agreement. The Company shall remain responsible to Everlast and International Brand for all acts and omissions of the subsidiary, Sports Nutrition Products Inc.
The Everlast License Agreement includes a clause stating that Manchester Capital Incorporated will guarantee that the Licensee shall perform all of its obligations and duties under the License Agreement. If the Licensee defaults in the payment when due of any amount it is obliged to pay to Licensor under the License Agreement, or arising from its termination, Manchester Capital is unconditionally responsible to pay that amount to Licensor in the manner prescribed in the License Agreement as if it were the Licensee.
The Royalty Calculation, as per the terms of the agreement, are as follows: In 2013, 7 % of Net Retail Sales and 7% of 60% of Direct Response Sales Revenue; in 2014, 8 % of Net Retail Sales and 8% of 60% of Direct Response Sales Revenue; in 2015, 9 % of Net Retail Sales and 9% of 60% of Direct Response Sales Revenue; in 2016 onwards, 10 % of Net Retail Sales and 10% of 60% of Direct Response Sales Revenue. The Annual Minimum Guaranteed Royalty is $ 120,000 in 2014, $ 235,000 in 2015, $ 320,000 in 2016, $ 345,000 in 2017 and in 2018 onwards, if the Agreement remains in force, will be 75% of the previous Year’s Royalty Calculation or the previous Year’s Annual Minimum Guaranteed Royalty plus 10%, whichever is greater.
The agreement was terminated on December 31, 2017. On January 17, 2019, Everlast World’s Boxing Headquarters Corp. (“Everlast”) filed a counter claim against the Company and other defendants. In that lawsuit, Everlast seeks payment from the defendants under a License Agreement dated June 4, 2013, for $ 425,555 in unpaid royalties allegedly due and owing under the License Agreement and interest on the allegedly unpaid royalties of $ 96,265 , which interest allegedly continues to accrue. Everlast has also sought all costs, expenses, and legal fees incurred by Everlast in collecting monies that it claims are due under the License Agreement. On February 26, 2020, the court in the Everlast matter issued an Opinion and Order granting a motion to dismiss all of the Company’s claims against Everlast and granting a motion for judgment on the pleadings as to liability against the Company. The Court left open the question of damages to be awarded to Everlast. The Company had requested that the parties participate in settlement discussions before a magistrate judge or, in the alternative, that Everlast engage in limited discovery on these matters. No settlement was reached. On October 15, 2020, the Court in the Everlast case ordered, adjudged and decreed that Plaintiff Everlast have judgment and recover a total of $ 738,946 from the Company as follows:
1. $ 425,000 representing royalty payments due to Everlast;
2. Interest on royalty payments computed through October 15, 2020, in the sum of $ 242,920 ;
3. Costs and attorneys’ fees in the sum of $ 71,026
On November 17, 2021, The Company entered Into a Stipulation (“Stipulation”) of the litigation captioned Everlast World’s Boxing Headquarters Corp. (“Everlast”) , Plaintiff vs. Trident Brands, Inc. and Manchester Capital Inc., Defendants, Waukesha County Court Case No. 21 TJ 90. Under the terms of the Stipulation, the Company agreed to pay Everlast on or before February 15, 2022, the sum of $650,000 in full satisfaction of the Everlast’s judgment against the Company in the amount of $738,946. Under the Stipulation, except for the first $ 250,000 of capital raised, the Company is required to pay Everlast 20 % of the gross amount of any capital raising transaction, until the full $650,000 is paid, provided however that the full $650,000 was required to have been paid no later than February 15, 2022.
The Company failed to pay Everlast the full $650,000 by February 15, 2022, as a result of which the Company is obligated to pay Everlast the judgment amount of $738,945, plus applicable interest (a total of $ 750,713 as of August 21, 2021) and attorney’s fees, less any payments made. The estimated liability as of May 31, 2022 due to accrued interest is $ 908,799 which the Company has fully accrued. The Company is currently in litigation with Everlast regarding Everlast's methods to collect the judgements.
Banc of America Leasing and Capital
On December 1, 2020, Bank of America Leasing and Capital, LLC filed a legal action against the Company in the Superior Court for the State of California, County of San Mateo (Case NO. 20-CIV-05306), alleging breach of contract. The claim arises out of a software services contract between the Company and Oracle Corporation. Bank of America Leasing and Capital, LLC acquired Oracle’s rights under the agreement. The plaintiff claims the Company is liable for damages in the amount of $ 217,000 plus interests and costs. The Company has not filed an answer to this complaint. On February 22, 2021, the plaintiff requested that the Court enter a default judgment against the Company. The Company intends to engage counsel and defend against this claim.
| 15 |

PIT Mycell
On June 3, 2019, the Company filed a lawsuit against PIT Mycell, LLC, William E. Peterson III, New Age Ventures, LLC, Volker Berl, and Mycell Technologies, LLC (“Mycell”) in the Superior Court in Bergen County, New Jersey, Civil Action No. BER-L-004198-19, in which the Company seeks to require the defendants to perform under and allow the enforcement of certain notes made by Mycell and acquired by the Company in September 2017. The notes are past their stated maturity date of December 31, 2016. The Company also alleges that the parties had entered into a written Settlement Agreement Letter of Intent dated March 14, 2019 (the “Settlement”), but that the defendants repudiated it shortly thereafter. The notes had been the subject of an earlier lawsuit in Virginia in state court in Fairfax County between the Company and PIT Mycell, LLC that the Settlement was intended to resolve. The Company seeks to enforce the notes and the Settlement in the New Jersey lawsuit and requests actual damages in an amount to be proven at trial, attorneys’ fees and litigation costs, specific performance requiring certain defendants to enforce obligations under the notes against Mycell, specific performance requiring the defendants to execute a final Settlement Agreement consistent with the Settlement, an order permitting foreclosure on the collateral for the notes, and declaratory relief. On January 24, 2020, the New Jersey court denied Defendant’s Motions to dismiss the case. The parties have engaged in written discovery and exchanged productions of documents. Mycell filed for bankruptcy on November 25, 2020. The bankruptcy is completed and the Company no longer has a claim on the new company that has since emerged from bankruptcy.
Contingencies
The Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. If any legal matter, that may arise, were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s would reflect any potential claim in the consolidated financial statements for that reporting period.
NOTE 9. SUBSEQUENT EVENTS
On March 3, 2022, the Board authorized the following executive compensation plan:
| - | Upon the closing of an initial financing (greater than $2,000,000) then the CEO shall be issued 1.5% of the fully diluted common stock and the Chairman shall receive 1.0% of the fully diluted common stock ; |
| - | Upon the uplisting of the Company to the New York Stock Exchange (NYSE) or the Nasdaq (whether by merger or operations), then the CEO shall be issued 1.5% of the fully diluted common stock and the Chairman shall receive 1.0% of the fully diluted common stock; |
| - | Upon the closing of an acquisition, then the CEO shall be issued a bonus equal 3% of the total enterprise value of the deal and the Chairman shall receive 2% of the total enterprise value of the deal, which may at the option of the Company be paid in cash, or stock. If the bonus is paid in stock, then the stock shall be issued at a 20% discount to the market; |

The Company's Board of Directors also established the following compensation and bonus plan for its CEO and reserved some bonus stock in anticipation of hiring a COO and CFO:
| Total Revenue* (in millions) | Adjusted EBITDA* | Exercise Price** | Percent of Shares CEO *** | Percent of Shares COO*** | Percent of Shares CFO*** |
| $ | 1.00 | N/A | $ | 0.05 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 2.00 | N/A | $ | 0.125 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 4.00 | N/A | $ | 0.25 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 8.00 | $ | 80,000 | $ | 0.50 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 12.00 | $ | 150,000 | $ | 0.75 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 18.00 | $ | 225,000 | $ | 1.00 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 30.00 | $ | 450,000 | $ | 1.50 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 45.00 | $ | 675,000 | $ | 2.50 | 1.00 | % | 0.25 | % | 0.25 | % |
| $ | 75.00 | $ | 1,312,500 | $ | 5.00 | 1.00 | % | 0.25 | % | 0.25 | % |

* Until the Company achieves the $8 million revenue target, the executive will earn 100% of eligible shares upon attainment of the relevant revenue target. Commencing with achievement of the $8 million revenue target, the executive will earn 75% of the eligible shares upon attainment of the revenue target and will earn 25% of the eligible shares upon attainment of the Adjusted EBITDA target.
** Exercise Price shall be the lower of the Exercise Price set forth above or a 20% discount to the 5-day VWAP
** Exercise Price shall not be adjusted accordingly for any stock splits, as these Exercise Prices are after giving effect to the split.
*** Percent of Shares shall be based on the number of fully diluted common shares
On March 3, 2022, the Board also authorized the award of 4,000,000 shares to the Company's employees. The shares will be vested immediately and issued all at once.
On April 4, 2022, the Company announced that it filed an amendment to its certificate of incorporation to: (1) authorize 29,320,432 shares of Preferred Stock which it will use to satisfy approximately $ 17.7 Million of principal and accrued interest due under certain convertible notes, representing a conversion rate of $ 0.60 per share, and (2) change the name of the corporation to SOLNI Group. The amendment authorizing the Preferred Shares was approved by a majority of the Company’s shareholders and was filed with the State of Nevada on March 31, 2022. The amendments are expected to be effective by September 30, 2022.
| 16 |

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
Forward Looking Statements
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the interim consolidated financial statements, and notes thereto, for the quarter ended May 31, 2022 contained under Item 1 of this Quarterly Report on Form 10-Q (“Form 10-Q”) and in conjunction with the annual consolidated financial statements, and notes thereto, contained in the Annual Report on Form 10-K for the fiscal year ended November 30, 2021 (“Form 10-K”). Unless otherwise indicated herein, the discussion and analysis contained in this MD&A includes information available through July 27, 2022.
Certain statements contained in this MD&A may constitute forward-looking statements as defined under securities laws. Forward-looking statements may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes, plans and objectives. In some cases, forward-looking statements can be identified by terms such as “anticipate”, “estimate”, “intend”, “project”, “potential”, “continue”, “believe”, “expect”, “could”, “would”, “should”, “might”, “plan”, “will”, “may”, “predict”, the negatives of such terms, and other similar expressions concerning matters that are not historical facts. To the extent any forward-looking statements contain future-oriented financial information or financial outlooks, such information is being provided to enable a reader to assess our financial condition, material changes in our financial condition, our results of operations, and our liquidity and capital resources. Readers are cautioned that this information may not be appropriate for any other purpose, including investment decisions.
Forward-looking statements contained in this MD&A are based on certain factors and assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Forward-looking statements are also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors are more fully described in the “Risk Factors” section at Item 1A of the Form 10-K.
Forward-looking statements contained in this commentary are based on our current estimates, expectations and projections, which we believe are reasonable as of the date of this report. You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. Other than as required under securities laws, we do not undertake to update any forward-looking information at any particular time.
All dollar amounts in this MD&A are expressed in thousands of U.S. dollars unless otherwise noted.
Results of Operations
The following summary of our results of operations should be read in conjunction with our unaudited consolidated financial statements for the three and six month periods ended May 31, 2022 and May 31, 2021.
| 17 |

Our operating results for three month periods ended May 31, 2022 and May 31, 2021 are summarized as follows:
| Three Months Ended | Three Months Ended |
| May 31, | May 31, |
| 2022 | 2021 |
| Revenues | $ | 125,280 | $ | 46,243 |
| Gross Profit | $ | (21,168 | ) | $ | 21,663 |
| Operating Expenses | $ | 528,103 | $ | 537,978 |
| Other Expenses | $ | 234,170 | $ | 200,008 |
| Net Loss | $ | (783,441 | ) | $ | (716,323 | ) |
| Add back: |
| Interest Expense | $ | 234,170 | $ | 200,008 |
| Depreciation | $ | -0- | $ | -0- |
| Amortization | $ | -0- | $ | -0- |
| EBITDA | $ | (549,271 | ) | $ | (516,315 | ) |

Revenues and Gross Profits
Sales for the three month period ended May 31, 2022 increased to $125,280 versus $46,243 in the prior period. The increase was the result of a special sale of raw material. Gross profit decreased to $(21,168) versus $21,663 or 46.8% of revenues. Other than this special sales of raw material, we currently have no revenue. If we are able to secure sufficient additional funding and needed inventory, we expect that our revenues will gradually recover. In addition, we intend to continue to look for distribution and supply chain partners to lower our costs.
Operating Expenses
Our operating expenses for the three month period ended May 31, 2022 and May 31, 2021 are summarized below:
| Three Months Ended May 31, | Three Months Ended May 31, |
| 2022 | 2021 |
| Professional Fees | $ | 46,341 | $ | 80,478 |
| General & Administrative Expenses | $ | 454,073 | $ | 422,304 |
| Marketing, Selling & Warehousing Expenses | $ | 8,477 | $ | 34,451 |
| Director’s Fees | $ | 18,000 | $ | -0- |
| Rent | $ | 1,212 | $ | 745 |

Operating expenses for the three month period ended May 31, 2022 were $528,103 as compared to $537,978 for the comparable period in 2021, a decrease of 1.8%. The decrease in our operating expenses was primarily due to a decrease in general & administrative expenses as a result of cost reductions and decreased marketing and selling expenses related to the decrease in sales. General & administrative expenses included a compensation expense of $120,000 for the authorized award of 4,000,000 shares to the Company's employees. Subject to raising additional capital, we expect our operating expenses to increase as we ramp up our selling activities.
| 18 |

Other Expenses
Other expenses for the three month period ended May 31, 2022 were $234,170 as compared to $200,008 for the comparable period in 2021, an increase of 1.2%. The increase of $34,162 was primarily due to an additional accrual of $29,726 for the Everlast liability. We expect interest expenses to remain constant.
Six Month Periods Ended May 31, 2022 and May 31, 2021
Our operating results for six month periods ended May 31, 2022 and May 31, 2021 are summarized as follows:
| SixMonths EndedMay 31,2022 | Six Months EndedMay 31,2021 |
| Revenues | $ | 125,280 | $ | 190,291 |
| Gross Profit | $ | (21,168 | ) | $ | 86,923 |
| Operating Expenses | $ | 945,412 | $ | 942,262 |
| Other Expenses | $ | 569,846 | $ | 400,341 |
| Net Loss | $ | (1,536,426 | ) | $ | (1,255,680 | ) |
| Add back: |
| Interest Expense | $ | 569,846 | $ | 400,341 |
| Depreciation | $ | -0- | $ | -0- |
| Amortization | $ | -0- | $ | -0- |
| EBITDA | $ | (966,580 | ) | $ | (855,339 | ) |

Revenues and Gross Profits
Sales for the six month period ended May 31, 2022 decreased to $125,280 versus $190,291 in the prior period. The decrease was due in part to the lack of inventory (out of stock of certain SKU’s), which also prevented us from fulfilling various purchase orders. Our lack of inventory is a result of not having sufficient capital to purchase inventory. Subject to receipt of additional funding, we expect this lack of supply to resolve over the next three months, at which time we expect our sales will begin to recover. Gross profit decreased to $(21,168) or (-16.9% of revenues) versus $86,923 (45.7% of revenues). We currently have no revenue. If we are able to secure sufficient additional funding and needed inventory, we expect that our revenues will gradually recover. In addition, we intend to continue to look for distribution and supply chain partners to lower our costs.
| 19 |

Operating Expenses
Our operating expenses for the six month period ended May 31, 2022 and May 31, 2021 are summarized below:
| SixMonths EndedMay 31,2022 | SixMonths EndedMay 31,2021 |
| Professional Fees | $ | 92,717 | $ | 94,127 |
| General & Administrative Expenses | $ | 805,232 | $ | 869,750 |
| Marketing, Selling & Warehousing Expenses | $ | 26,277 | $ | 61,481 |
| Director’s Fees | $ | 18,000 | $ | -0- |
| Rent | $ | 3,186 | $ | 1,904 |

Operating expenses for the six month period ended May 31, 2022 were $945,412 as compared to $942,262 for the comparable period in 2021, an increase of .3%. The increase in our operating expenses was primarily due to a compensation expense of $120,000 for the authorized award of 4,000,000 shares to the Company's employees and director's fees of $18,000 which offset a decrease in general & administrative expenses as a result of cost reductions and decreased marketing and selling expenses related to the decrease in sales. Subject to raising additional capital, we expect our operating expenses to increase as we ramp up our selling activities.
Other Expenses
Other expenses for the six month period ended May 31, 2022 were $569,846, compared to $400,341 in the comparable period in 2021. The increase of $169,505 was primarily due to an additional accrual of $169,854 for the Everlast liability. We expect interest expenses to remain constant.
Balance Sheet Data
The following table provides selected balance sheets data as at May 31, 2022 and November 30, 2021.
| Balance Sheet Data: | May 31, 2022 | November 30, 2021 |
| Cash | $ | 12,389 | $ | 7,653 |
| Total assets | $ | 749,357 | $ | 1,060,081 |
| Total liabilities | $ | 33,335,742 | $ | 32,230,040 |
| Stockholders’ (deficit) | $ | (32,586,385 | ) | $ | (31,169,959 | ) |

Strategic Orientation
Our objective is to provide our shareholders with solid returns through strategic investments across multiple consumer product and ingredient platforms. The platforms we are focusing on include:
| ● | Life science technologies and related products that have applications to a range of consumer products; |
| ● | Nutritional supplements and related consumer goods providing defined benefits to the consumer; and |
| ● | Functional foods and beverages ingredients with defined health and wellness benefits. |

| 20 |

We are building our business through strategic investments in high growth early stage consumer brands and functional ingredient platforms within segment/sectors which we believe offer sustainable commercial potential. We are focused on three core strategies underpinning our objectives:
| ● | To execute a multi-tier brand, supply-chain and innovation strategy to drive revenue; and |
| ● | To aggressively manage an asset light business model to drive a low cost platform. |

While we have yet to achieve profitability, we are endeavoring to make progress against our long term commercial objectives. Subject to receipt of sufficient capital, which we currently do not have, we anticipate that revenue and margin will increase as we strengthen distribution partnerships while capitalizing on product innovation, supply-chain optimization and brand equity within our current portfolio.
Liquidity and Capital Resources
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.
As of May 31, 2022, the Company had $12,389 in cash and a working capital deficit of $10,286,385. The Company also has generated losses and has an accumulated deficit as of May 31, 2022. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Need for Additional Capital
The current funds available to the company are not sufficient to fund its near term operations. The Company has an urgent need for additional capital, without which, the Company is unlikely to continue as a going concern. Unless management is able to obtain additional financing, the Company will not be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
As of May 31, 2022, the Company had $12,389 in cash and a working capital deficit of $10,286,385, compared to a deficit of approximately $8.9 million as of November 30, 2021 The approximate $1.4 million increase in working capital deficit was due primarily to an increase in accrued liabilities of $1.1 million, a decrease in prepaids of $0.2 million and a decrease in inventory of $0.1 million.
As disclosed under Item 3. Legal Proceedings, a judgment was entered against us in the Everlast matter in the amount of approximately $740,000, which has grown to more than $900,000 as of May 2022. In addition, the plaintiff in the Oracle matter has requested a default judgment against us. Accordingly, the Company is currently obligated to pay Everlast approximately $750,000 not including interest accrued since August 2021 and could be liable to pay Oracle at least $217,000 if the court enters a default judgment, in which case, the Company would be liable for in excess of $1 million in judgments, in the aggregate. If the Company is compelled to pay these liabilities, there would be a material adverse effect on the financial condition of the Company.
Because we have only minimal cash on hand, we are unable to implement our current business plan. Accordingly, we have an immediate need for additional capital to fund our operating activities. We currently have no revenues have had difficulty raising additional capital, so there is no assurance we will be able to grow our business or raise sufficient additional capital on acceptable terms or at all.
In order to remedy this liquidity deficiency, we are actively seeking to raise additional funds through the sale of equity and/or debt securities, and ultimately, we will need to generate substantial positive operating cash flows. Our internal sources of funds will consist of cash flows from operations, but not until we begin to realize additional revenues from the sale of our products and services. As previously stated, our operations are generating negative cash flows, and thus adversely affecting our liquidity. If we are unable to raise additional funds in the near term, we will not be able to implement our business plan, in which case there would be a material adverse effect on our results of operations and financial condition.
In the event we do not generate sufficient funds from revenues or financing through the issuance of common stock or from debt financing, we will be unable to implement our business plan and pay our obligations as they become due, any of which circumstances would have a material adverse effect on our business prospects, financial condition, and results of operations. The accompanying financial statements do not include any adjustments that might be required should we be unable to recover the value of our assets or satisfy our liabilities.
Based on our limited availability of funds we expect to spend minimal amounts on product development, sales and marketing and capital expenditures. We expect to fund any future product development expenditures through a combination of cash flows from operations and proceeds from equity and/or debt financing. If we are unable to generate positive cash flows from operations, and/or raise additional funds (either through debt or equity), we will be unable to fund our product development expenditures, in which case, there could be material and adverse effect on our business and results of operations.
| 21 |

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Contractual Obligations
Except for the transactions disclosed in this Report, there have been no material changes outside the normal course of business in our contractual obligations since February 28, 2022.
Critical Accounting Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, related revenues and expenses, and disclosure of gain and loss contingencies at the date of the financial statements. The estimates and assumptions made require us to exercise our judgment and are based on historical experience and various other factors that we believe to be reasonable under the circumstances. We continually evaluate the information that forms the basis of our estimates and assumptions as our business and the business environment generally changes. The use of estimates is pervasive throughout our financial statements. There have been no material changes to the critical accounting estimates disclosed under the heading “Critical Accounting Estimates” in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, of the Form 10-K.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company we are not required to provide this information.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and the principal financial officer, we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective such that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating to our company, particularly during the period when this report was being prepared.
Changes in Internal Controls Over Financial Reporting
Our management, with the participation of our principal executive officer and principal financial officer have concluded that there have been no changes in our internal control over financial reporting that occurred during the fiscal quarter ended May 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 22 |

PART II. OTHER INFORMATION
ITEM 6. EXHIBITS
The following exhibits are included with this quarterly filing:
| Exhibit No. | Description |
| 3.1 | Articles of Incorporation as amended (incorporated by reference to our Annual Report on form 10-K for the year ended November 30,2021 filed with the SEC on April 14, 2022*) |
| 3.2 | Bylaws* |
| 31.1 | Sec. 302 Certification of Chief Executive Officer |
| 31.2 | Sec. 302 Certification of Chief Financial Officer |
| 32.1 | Sec. 906 Certification of Chief Executive Officer |
| 32.2 | Sec. 906 Certification of Chief Financial Officer |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |

_________________
* Document is incorporated by reference and can be found in its entirety in our Registration Statement on Form SB-2, SEC File Number 333-148710, at the Securities and Exchange Commission website at www.sec.gov.
| 25 |

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Trident Brands Incorporated |
| Date: July 27, 2022 | By: | /s/ Michael Friedman |
| Michael Friedman |
| (Chief Executive Officer) |
| By: | /s/ Peter Salvo |
| Peter Salvo |
| (Principal Financial Officer) |

| 26 |


Question: How do you calculate the average monthly net loss from November 30, 2021 up to May 31, 2022 in dollars?

Python solution:
def solution():
    #Define variables name and value

    initial_accumulated_deficit = 42205049  # Accumulated Deficit on November, 2021

    final_accumulated_deficit = 43598832  # Accumulated Deficit on May, 2022

    #Do math calculation to get the answer
    total_net_loss = final_accumulated_deficit - initial_accumulated_deficit  # Total net loss for the period
    num_months = 6  # Number of months from November, 2021 to May, 2022
    average_monthly_net_loss = total_net_loss / num_months  # Average monthly net loss
    return average_monthly_net_loss


Answer: 232297.1666666667